Our clinical trials

An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With BI 754091 to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Check Point Inhibitor naïve Patient With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Progressed During or After First Line Platinum-based Treatment.

A phase ib, open-label, multicenter study evaluating the safety and efficacy of ipatasertib in combination with atezolizumab and paclitaxel or nab-paclitaxel in patients with locally advanced or metastatic triple- negative breast cancer

Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer